Chronic nephritic syndrome with diffuse membranous glomerulonephritis
ICD-10 N03.2 is a billable code used to indicate a diagnosis of chronic nephritic syndrome with diffuse membranous glomerulonephritis.
Chronic nephritic syndrome with diffuse membranous glomerulonephritis is characterized by persistent inflammation of the glomeruli, leading to significant proteinuria, hematuria, and hypertension. This condition is often a result of immune-mediated damage to the glomerular membrane, which becomes thickened due to the deposition of immune complexes. Patients typically present with symptoms such as edema, fatigue, and foamy urine due to high levels of protein loss. Renal biopsy findings often reveal diffuse thickening of the glomerular capillary walls, with subepithelial immune complex deposits visible under electron microscopy. Management of this condition involves addressing the underlying cause, controlling blood pressure, and managing proteinuria, often with the use of corticosteroids or immunosuppressive agents. Regular monitoring of renal function and laboratory parameters is essential to assess disease progression and treatment efficacy.
Detailed clinical notes on symptoms, lab results, and treatment plans are essential.
Patients presenting with edema, hypertension, and abnormal urinalysis findings.
Ensure accurate documentation of renal function tests and biopsy results to support coding.
Pathology reports must clearly describe biopsy findings and any immunofluorescence studies performed.
Biopsy evaluations for patients with suspected glomerulonephritis.
Pathology findings should correlate with clinical symptoms for accurate coding.
Used when a renal biopsy is performed to confirm diagnosis.
Document indication for biopsy, consent, and findings.
Nephrologists must ensure that the biopsy results correlate with clinical findings.
Key symptoms include persistent proteinuria, hematuria, edema, and hypertension. Patients may also experience fatigue and foamy urine due to high protein levels.
Diagnosis is typically made through a combination of clinical evaluation, urinalysis showing proteinuria and hematuria, and renal biopsy to confirm the presence of diffuse membranous glomerulonephritis.
